VEGFA and neoplasm: Therefore, anti-angiogenic therapy remains the gold standard in selected patients (VEGF-dependent favourable mRCC in all setting) and increases the efficacy of immunotherapy, modulating immune responses, increasing anticancer immune-trafficking and activity, through the regulation of tumor vessels and reducing suppressing cytokines and infiltrating T regs [54, 56, 57].